| Matthew I Fogg, MD | |
|
470 Sentry Pkwy E, Ste 200, Blue Bell, PA 19422-2324 | |
| (610) 825-5800 | |
| (610) 397-0980 |
| Full Name | Matthew I Fogg |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 25 Years |
| Location | 470 Sentry Pkwy E, Blue Bell, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114920220 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | MD417599 (Pennsylvania) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Psf Pllc | 1557265543 | 98 |
News Archive
The National Association of State Controlled Substances Authorities (NASCSA) announced receipt of a $200,000 grant from Purdue Pharma L.P. today at the organization's 25th annual conference in San Diego. The grant is part of Purdue Pharma's ongoing efforts to support the operation, expansion and awareness of appropriately-designed state prescription drug monitoring programs, which can be an effective tool to address prescription drug abuse and diversion.
"Democrats and Republicans are waging an intense fight for the loyalties of older voters, who turn out reliably in midterm elections and whose fears have been stoked this year by the battle over health care," The Wall Street Journal reports. Republicans are telling the the health law "will cripple Medicare by cutting $500 billion from the program," while Democrats say the GOP plans to "gut Social Security." Seniors rely on one program as the payer for much of their health care, and the other for financial support.
Eisai Inc. today announced that the U.S. Food and Drug Administration has approved BANZEL Oral Suspension, 40 mg/mL, for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults.
In the 21st century, state-of-the-art anti-aging technologies may extend human lifespans at an unprecedented rate, bringing with them a host of social and economic challenges, says biologist Shripad Tuljapurkar of Stanford University.
A medical device for Cystic Fibrosis (CF) sufferers which lessens their exposure to infections resulting in fewer doctors' visits, reduced antibiotic usage and shorter hospital stays, is expected to be market ready within two years.
› Verified 4 days ago
| Entity Name | Allergy & Asthma Specialists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144290016 PECOS PAC ID: 2466422670 Enrollment ID: O20040727000474 |
News Archive
The National Association of State Controlled Substances Authorities (NASCSA) announced receipt of a $200,000 grant from Purdue Pharma L.P. today at the organization's 25th annual conference in San Diego. The grant is part of Purdue Pharma's ongoing efforts to support the operation, expansion and awareness of appropriately-designed state prescription drug monitoring programs, which can be an effective tool to address prescription drug abuse and diversion.
"Democrats and Republicans are waging an intense fight for the loyalties of older voters, who turn out reliably in midterm elections and whose fears have been stoked this year by the battle over health care," The Wall Street Journal reports. Republicans are telling the the health law "will cripple Medicare by cutting $500 billion from the program," while Democrats say the GOP plans to "gut Social Security." Seniors rely on one program as the payer for much of their health care, and the other for financial support.
Eisai Inc. today announced that the U.S. Food and Drug Administration has approved BANZEL Oral Suspension, 40 mg/mL, for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults.
In the 21st century, state-of-the-art anti-aging technologies may extend human lifespans at an unprecedented rate, bringing with them a host of social and economic challenges, says biologist Shripad Tuljapurkar of Stanford University.
A medical device for Cystic Fibrosis (CF) sufferers which lessens their exposure to infections resulting in fewer doctors' visits, reduced antibiotic usage and shorter hospital stays, is expected to be market ready within two years.
› Verified 4 days ago
| Entity Name | Psf Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881785947 PECOS PAC ID: 1557265543 Enrollment ID: O20210807000032 |
News Archive
The National Association of State Controlled Substances Authorities (NASCSA) announced receipt of a $200,000 grant from Purdue Pharma L.P. today at the organization's 25th annual conference in San Diego. The grant is part of Purdue Pharma's ongoing efforts to support the operation, expansion and awareness of appropriately-designed state prescription drug monitoring programs, which can be an effective tool to address prescription drug abuse and diversion.
"Democrats and Republicans are waging an intense fight for the loyalties of older voters, who turn out reliably in midterm elections and whose fears have been stoked this year by the battle over health care," The Wall Street Journal reports. Republicans are telling the the health law "will cripple Medicare by cutting $500 billion from the program," while Democrats say the GOP plans to "gut Social Security." Seniors rely on one program as the payer for much of their health care, and the other for financial support.
Eisai Inc. today announced that the U.S. Food and Drug Administration has approved BANZEL Oral Suspension, 40 mg/mL, for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults.
In the 21st century, state-of-the-art anti-aging technologies may extend human lifespans at an unprecedented rate, bringing with them a host of social and economic challenges, says biologist Shripad Tuljapurkar of Stanford University.
A medical device for Cystic Fibrosis (CF) sufferers which lessens their exposure to infections resulting in fewer doctors' visits, reduced antibiotic usage and shorter hospital stays, is expected to be market ready within two years.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew I Fogg, MD 9800 Shelbyville Rd Ste 220, Louisville, KY 40223-2992 Ph: (502) 429-8585 | Matthew I Fogg, MD 470 Sentry Pkwy E, Ste 200, Blue Bell, PA 19422-2324 Ph: (610) 825-5800 |
News Archive
The National Association of State Controlled Substances Authorities (NASCSA) announced receipt of a $200,000 grant from Purdue Pharma L.P. today at the organization's 25th annual conference in San Diego. The grant is part of Purdue Pharma's ongoing efforts to support the operation, expansion and awareness of appropriately-designed state prescription drug monitoring programs, which can be an effective tool to address prescription drug abuse and diversion.
"Democrats and Republicans are waging an intense fight for the loyalties of older voters, who turn out reliably in midterm elections and whose fears have been stoked this year by the battle over health care," The Wall Street Journal reports. Republicans are telling the the health law "will cripple Medicare by cutting $500 billion from the program," while Democrats say the GOP plans to "gut Social Security." Seniors rely on one program as the payer for much of their health care, and the other for financial support.
Eisai Inc. today announced that the U.S. Food and Drug Administration has approved BANZEL Oral Suspension, 40 mg/mL, for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults.
In the 21st century, state-of-the-art anti-aging technologies may extend human lifespans at an unprecedented rate, bringing with them a host of social and economic challenges, says biologist Shripad Tuljapurkar of Stanford University.
A medical device for Cystic Fibrosis (CF) sufferers which lessens their exposure to infections resulting in fewer doctors' visits, reduced antibiotic usage and shorter hospital stays, is expected to be market ready within two years.
› Verified 4 days ago
Dr. Patrick Michael Vannelli, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 470 Sentry Pkwy E, Suite 200, Blue Bell, PA 19422 Phone: 610-825-5800 Fax: 610-397-0980 | |
Mark S Lepore, MD Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 470 Sentry Pkwy E, Ste 200, Blue Bell, PA 19422 Phone: 610-825-5800 Fax: 610-397-0980 | |
Niti Agarwal, Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 470 Sentry Pkwy E Ste 200, Blue Bell, PA 19422 Phone: 610-825-5800 Fax: 610-397-0980 | |
Nora J Lin, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 470 Sentry Pkwy E, Ste 200, Blue Bell, PA 19422 Phone: 610-825-5800 Fax: 610-397-0980 | |
Robert Anolik, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 470 Sentry Pkwy E, Ste 200, Blue Bell, PA 19422 Phone: 610-825-5800 Fax: 610-397-0980 | |
Dr. David Stuart Krause, MD Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 147 Sawgrass Drive, Blue Bell, PA 19422 Phone: 215-280-9425 |